| Identification | Back Directory | [Name]
NARATRIPTAN HYDROCHLORIDE (125 MG)F0C3600.998MG/MG(AI) | [CAS]
143388-64-1 | [Synonyms]
Amerge.
Naramig
GR-85548A
Nariptan Hydrochloride
Naratriptan Nitrate USP
Naratriptan Hydrochloride
Naratriptan monohydrochloride
Naratriptan Hydrochloride (125 mg)
NARATRIPTAN HYDROCHLORIDE (125 MG)F0C36099%8MG/MG(AI)
NARATRIPTAN HYDROCHLORIDE (125 MG)F0C3600.998MG/MG(AI)
1H-Indole-5-ethanesulfonaMide,N-Methyl-3-(1-Methyl-4-piperidinyl
N-Methyl-3-(1-methylpiperidin-4-yl)-1H-indole-5-ethanesulfonamide hydrochloride
N-Methyl-3-(1-methyl-4-piperidinyl)-1H-indole-5-ethanesulfonamide hydrochloride
1H-Indole-5-ethanesulfonamide,N-methyl-3-(1-methyl-4-piperidinyl)-,hydrochloride
N-Methyl-2-[3-(1-methyl-4-piperidyl)-1H-indol-5-yl]-ethanesulfonamide Hydrochloride
N-Methyl-2-(3-(1-Methylpiperidin-4-yl)-1H-indol-5-yl)ethanesulfonaMide hydrochloride
1H-Indole-5-ethanesulfonaMide,N-Methyl-3-(1-Methyl-4-piperidinyl)-, hydrochloride (1:1) | [Molecular Formula]
C17H25N3O2S.ClH | [MDL Number]
MFCD08141821 | [MOL File]
143388-64-1.mol | [Molecular Weight]
371.93 |
| Chemical Properties | Back Directory | [Appearance]
Beige Solid | [Melting point ]
234-236°C | [storage temp. ]
-20°C Freezer | [solubility ]
H2O: ≥10mg/mL | [form ]
powder | [color ]
white to off-white | [InChIKey]
AWEZYKMQFAUBTD-UHFFFAOYSA-N |
| Hazard Information | Back Directory | [Chemical Properties]
Beige Solid | [Uses]
It is a triptan drug and is used for the treatment of migraine headaches | [Uses]
laxative | [Uses]
Naratriptan(Amerge and Naramig) is a triptan drug that is used for the treatment of migraine headaches. It is a selective 5-hydroxytryptamine1 receptor subtype agonist | [Description]
Naramig was launched in Germany, Sweden and the UK for use in migraine.
It is chemically available via a number of related synthetic routes all having about
three steps starting from 5-bromoindole. It is a new serotonin 5-HT1B/1D receptor
antagonist with modest affinity for 5-HT1a, and very weak affinity for 5-HT3 receptors. It
has little or no affinity for a wide range of non-serotonin receptors including a- and padrenoceptors,
dopamine, neurokinin NK1, and opiate receptors. It mediates
vasoconstriction in cerebral vasculature (extra cerebral intracranial vessels), reduces
neurogenic inflammation, and inhibits responses mediated by the trigeminal nerves. It
has a 6- and 3-fold greater affinity for 5-HT1B, and 5-HT1D, receptors, respectively, than
sumatriptan which translates to a 2-3 fold increase in potency. The reoccurance of
headache was less compared to sumatriptan, zolmitriptan and rizatriptan. Naramig
had no clinical effects on blood pressure or heart rate, had a long duration of action
with very good tolerability, and has high oral bioavailability. | [Originator]
Glaxo Wellcome (UK) | [Brand name]
Amerge (GlaxoSmithKline). |
|
|